Clinical Trial: NCT05991973
Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Zhejiang University |
| Information Provided By: | Zhejiang University |
| Last Update Posted: | 2025-12-05 |
Study Overview
Brief Summary
Clinical Study on the Safety and Effectiveness of low-dose chidamide maintenance therapy after allogeneic hematopoietic stem cell transplantation for T-cell acute lymphoblastic leukemia or T-cell lymphomas.
Official Title
A Phase ll, Multi-center, Single-arm Clinical Study of Low-dose Chidamide Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas
Conditions
T Lymphoblastic Leukemia/Lymphoma
Intervention / Treatment
- Drug: Chidamide
Other Study ID Numbers
- IIT20230004C-R2
Start Date (Actual)
2023-07-15
Primary Completion Date (Actual)
2025-06-01
Study Completion Date (Actual)
2025-07-01
Enrollment (Actual)
44
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Zhejiang University |
| Information Provided By: | Zhejiang University |
| Last Update Posted: | 2025-12-05 |
Study Overview
Brief Summary
Clinical Study on the Safety and Effectiveness of low-dose chidamide maintenance therapy after allogeneic hematopoietic stem cell transplantation for T-cell acute lymphoblastic leukemia or T-cell lymphomas.
Official Title
A Phase ll, Multi-center, Single-arm Clinical Study of Low-dose Chidamide Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas
Conditions
T Lymphoblastic Leukemia/Lymphoma
Intervention / Treatment
- Drug: Chidamide
Other Study ID Numbers
- IIT20230004C-R2
Start Date (Actual)
2023-07-15
Primary Completion Date (Actual)
2025-06-01
Study Completion Date (Actual)
2025-07-01
Enrollment (Actual)
44
Study Type
Interventional
Phase
Phase 2